Drugs aim to shrink facial tumors, spare patients from disfiguring surgery
NCT ID NCT05929664
Summary
This study is testing whether giving one or two immunotherapy drugs before surgery can shrink advanced basal cell carcinomas on the head and neck. The goal is to see if shrinking the tumor first allows surgeons to perform a less extensive operation, potentially preserving important facial features and function. About 70 patients will receive several infusions of the drugs over weeks before their scheduled surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Thomas Jefferson University Hospital
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Miami Health System
RECRUITINGMiami, Florida, 33136, United States
Contact
-
Vanderbilt University
RECRUITINGNashville, Tennessee, 37232, United States
Contact
Conditions
Explore the condition pages connected to this study.